Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 6,348 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36. Following the transaction, the insider directly owned 61,804 shares in the company, valued at $1,997,505.28. The trade was a 9.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.75, for a total value of $252,469.75.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $33.27, for a total value of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total value of $6,748,879.30.
• On Wednesday, October 15th, David Malcom Rodman sold 10,369 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $43.01, for a total value of $445,970.69.

Mineralys Therapeutics Price Performance

NASDAQ MLYS opened at $31.38 on Friday. The company has a market cap of $2.48 billion, a P/E ratio of -10.64 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $47.65. The company has a 50-day moving average of $38.51 and a 200-day moving average of $30.91.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. As a group, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Institutional Investors Weigh In On Mineralys Therapeutics

Large investors have recently modified their holdings of the stock. RA Capital Management L.P. lifted its position in Mineralys Therapeutics by 19.1% during the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after acquiring an additional 1,176,470 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Mineralys Therapeutics by 29.8% during the third quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after purchasing an additional 692,550 shares in the last quarter. Caligan Partners LP lifted its position in shares of Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after purchasing an additional 755,302 shares in the last quarter. Suvretta Capital Management LLC boosted its stake in shares of Mineralys Therapeutics by 22.2% in the third quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company’s stock valued at $80,850,000 after purchasing an additional 387,641 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Mineralys Therapeutics by 0.3% during the 3rd quarter. Franklin Resources Inc. now owns 1,809,768 shares of the company’s stock valued at $68,626,000 after purchasing an additional 6,171 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on MLYS. HC Wainwright increased their target price on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Wells Fargo & Company upped their price target on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus increased their target price on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $47.43.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.